Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / AIM ImmunoTech===Rintatolimod
Entity

AIM ImmunoTech===Rintatolimod

Tracked across 1 events · 9 articles · First seen Feb 05, 2026 · Last active Feb 23, 2026

Sentiment
70
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
AIM ImmunoTech Rintatolimod Pancreatic Cancer Trial Milestones
AIM ImmunoTech===Rintatolimod (rintatolimod) is AIM ImmunoTech Inc.'s lead drug product, being evaluated in a Phase 2 clinical study for metastatic pancreatic cancer. Promising Progression-Free Survival and Overall Survival were seen in Phase 1, and no significant toxicity has been reported in Phase 2, with subjects reporting high quality of life.
Feb 05, 2026 · 9 articles
Relationships (1)
AIM ImmunoTech lead product ↔ AIM ImmunoTech===Rintatolimod AIM ImmunoTech===Rintatolimod is the lead drug product being developed by AIM Im
NEWSDESK
Track AIM ImmunoTech===Rintatolimod live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.